Introduction
============

The Danish Heart Failure Registry (DHFR) is a nationwide registry established in 2003 as a part of a large nationwide quality improvement initiative aimed at monitoring and improving the quality of care for patients with specific severe diseases, including heart failure (HF).[@b1-clep-8-497] Reporting to the DHFR is mandatory for all hospital departments treating patients with incident HF. The DHFR achieved complete nationwide coverage in 2005.

Aim of database
===============

The aim of the DHFR is to monitor and support implementation of evidence-based treatment and care of patients with incident HF, and it is anticipated that it will improve the overall performance in patients with HF.

Study population
================

The DHFR includes data on inpatients and outpatients with incident HF. The HF diagnosis is made by a cardiologist using the criteria of the European Society of Cardiology.[@b2-clep-8-497] At discharge or at the first outpatient contact, patients with one of the following diagnoses (primary diagnosis) are screened for inclusion in the DHFR: I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.9, I50.0, I50.1, and I50.9. All diagnoses are made in accordance with the International Classification of Diseases 10th edition, which has been used for all admissions and outpatient contacts in Denmark since 1995.

Patients enrolled in the DHFR have to meet the following inclusion criteria: age 18 years or older, a first time hospital contact with HF as the primary diagnosis, and symptoms of HF, usually dyspnea, increased fatigue, fluid retention, andobjective signs of HF at rest, for example, reduced systolic function and/or diastolic dysfunction/elevated filling pressure and/orclinical response to specific HF treatment.

Thus, enrollment in the registry requires both manifestation of symptoms and objective signs of HF at rest and/or response to treatment of HF.

Exclusion criteria are previously verified diagnosis and treatment of HF, isolated right-sided HF, and HF secondary to valvular heart diseases, noncorrectable structural heart diseases, or tachycardia-induced HF (often atrial fibrillation). Furthermore, patients discharged with a diagnosis of acute myocardial infarction and concomitant HF are not included. These patients will be included if they are later hospitalized with HF or are referred to an outpatient cardiology clinic for treatment of HF.

Only patients with a Danish unique personal identification number (CPR number) are enrolled in the database, allowing accurate linkage between the DHFR and other nationwide administrative registries at the individual level. The decision to register a patient in the DHFR is made by a cardiologist to ensure the validity of the incident HF diagnosis according to the inclusion and exclusion criteria. By July 2015, the DHFR contained data on \~42,400 patients with incident HF. Each year, 3,700--3,900 patients with incident HF are registered in the DHFR.

Patients in the DHFR are selected in accordance with the exclusion criteria to establish a homogeneous population with HF. Thus, the DHFR will not reflect the total incidence of HF in the general Danish population due to inclusion and exclusion criteria. Moreover, less-severe cases of HF may be treated in the primary health care sector (general practice) and these cases are not recorded in the DHFR.

Main variables
==============

The variables recorded in the DHFR are related to basic characteristics, prognostic factors, diagnostic tests, functional capacity (symptom severity), pharmacological therapy, nonpharmacological therapy, readmission, and mortality ([Table 1](#t1-clep-8-497){ref-type="table"}). The quality indicators consist of five processes and two outcome indicators[@b3-clep-8-497] defined by the DHFR multi disciplinary board to monitor good clinical quality of treatment and care for patients with incident HF. The indicators are echocardiography, New York Heart Association functional classification, medications, physical training, patient education, rate of readmission, and mortality ([Table 2](#t2-clep-8-497){ref-type="table"}). Both the prognostic factors and the evidence-based quality indicators are based on national[@b4-clep-8-497] and international guidelines.[@b2-clep-8-497],[@b5-clep-8-497]

The use of echocardiography and New York Heart Association functional classification, 4-week readmission rate, and 1-year mortality are reported for all patients, whereas the use of angiotensin converting enzyme/angiotensin II antagonist inhibitors and beta-blockers, physical training, and patient education are evaluated in patients with systolic HF and left ventricular ejection fraction ≤40%. The use of mineralocorticoid receptor antagonist is evaluated in patients with left ventricular ejection fraction ≤35%.

Until now, the DHFR only contains information about patients with incident HF. At the audit conducted in 2015, the multidisciplinary board decided to supplement the registry with qualitative indicators for treatment status of the patients' treatment 1 year after diagnosis.

Data are registered for patients with HF admitted to hospital or at first outpatient visit by a cardiologist and the nursing staff. The process for registration of data has been developed to ensure data accuracy and for standardizing procedures for all clinicians.[@b6-clep-8-497]

The DHFR board is obliged to ensure that the indicators reflect the quality of HF treatment and that the collection of data is simple and feasible in routine clinical settings. Systematic literature reviews are performed regularly, and the latest review was conducted in 2015.[@b7-clep-8-497]

Local, regional, and national audits are conducted yearly. Performance data, completeness of registered patients, and variables are reported for each hospital department, region, and at a national level, making comparison of data possible.

At the annual national audit in the DHFR, the indicators and standards for good clinical quality in treatment and care for patients with HF are discussed and recommendations are reported back to clinicians and communicated to the public in the final annual report. Furthermore, the board decides whether any changes to the quality measures are warranted, and discusses potential new indicators.

In 2014 and 2015, all indicators were met at a national level.[@b8-clep-8-497] The coverage and completeness of indicator variables and prognostic factors from 2004 to 2015 are shown in [Table 3](#t3-clep-8-497){ref-type="table"}. The completeness of the reported variables for each indicator was between 91% and 100% in 2015.[@b8-clep-8-497]

Only patients with a first time primary diagnosis of HF are included in the registry. We assume that careful screening of the patients by a cardiologist means that virtually all patients included in the database have HF. But a precise validation of the accuracy has not been performed.

The coverage of the DHFR is routinely evaluated by matching data with the administrative data in the Danish National Patient Register,[@b9-clep-8-497] which includes data on all hospital contacts in Denmark since 1977. A total of 82% of incident HF cases had been recorded in the DHFR in 2015.[@b8-clep-8-497] This relatively low coverage may partly be explained by patients being treated for HF in the hospital and, thus, registered accordingly in the Danish National Patient Register, but not meeting the inclusion/exclusion criteria for entry into the DHFR. To obtain high coverage of the registry, a continuous effort by the departments is performed to review the lists of inpatients and outpatients with the primary diagnosis of HF and to assess whether the inclusion and exclusion criteria in the DHFR are fulfilled.

Follow-up
=========

Six of the seven indicators selected in the DHFR are related to care processes and outcome within a period of 12 weeks from the date for first contact to either hospital or outpatient clinic. Information on the seventh indicator on 1-year mortality is obtained from the Danish Civil Registration System,[@b10-clep-8-497] where vital status is updated continuously.

The participating departments receive regular feedback on their performance regarding the process indicators to ensure data validation and to support quality improvement.

Examples of research
====================

The population-based data and a high number of patients with incident systolic and nonsystolic HF makes the DHFR data suitable for clinical epidemiology research. A study has shown a substantial improvement in the DHFR process indicators from 2003 to 2010 among patients diagnosed with incident HF. In the same period, the 1-year mortality decreased from 20.5% to 12.8%.[@b11-clep-8-497]

An analysis based on the DHFR and demographic data indicates that HF is not diagnosed and treated adequately in people above 75 years.[@b12-clep-8-497] Studies on patients with systolic HF in the DHFR indicate equal effect of different types of angiotensin converting enzyme inhibitors and beta-blockers on mortality in patients with HF.[@b13-clep-8-497],[@b14-clep-8-497]

Administrative issues and funding
=================================

The DHFR is funded and operated by the Danish Clinical Registries,[@b15-clep-8-497] which are financed and owned by the five Danish regions. A clinical epidemiologist and a quality consultant from the Danish Clinical Registries are affiliated to the DHFR. The epidemiologist has the responsibility for the analytical methods, analysis of data, and interpretation of results in the DHFR. The quality consultant is responsible for communication and support to the DHFR as well as communication with the participating hospitals.

Conclusion
==========

The DHFR is a valuable tool for improving the quality of care for patients with HF and a valuable source for research. Since the establishment in 2003, the care of patients with incident HF admitted to the Danish hospitals and registered in the DHFR has improved with a higher level of achievement of quality indicators and declining 1-year mortality.

The DHFR exists only due to the continued efforts and contributions from the staff working with patients with HF. This paper was funded by the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation and administered by the Danish regions.
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###### 

Main variables in the Danish Heart Failure Registry

  Main group                                          Variable                                                                            Description/comments
  --------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Basic characteristics                               Civil registration number                                                           Unique personal identification number including date of birth and sex
  Age                                                                                                                                     
  Sex                                                                                                                                     
  Status of hospital contact                          Inpatient or outpatient                                                             
  Date of admission/outpatient contact                                                                                                    
  Date of discharge                                   Only hospitalized patients                                                          
  Status at discharge                                 Alive or dead                                                                       
  Discharge diagnosis                                 I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.9, I50.0, I50.1, and I50.9 (ICD-10)   
  Prognostic factors                                  Acute myocardial infarction                                                         Yes or no
  Stroke                                              Yes or no                                                                           
  Diabetes                                            Yes or no                                                                           
  COPD                                                Yes or no                                                                           
  Hypertension                                        Yes or no                                                                           
  Serum creatinine ≥150 μmol/L                        Yes or no                                                                           
  Electrocardiogram                                   Yes or no                                                                           
  Heart rhythm                                        SR, AF/AFL, or other                                                                
  Alcohol intake                                      ≤14/21 units per week, \>14/21 units per week or na                                 
  Smoking                                             Smoker, previous smoker, never smoker, or na                                        
  Diagnostic test                                     Echocardiography                                                                    Yes, date for echocardiography or no. If yes, the exact value for LVEF or LVEF \<25%, 25% ≤ LVEF ≤ 35%, 35% \< LVEF ≤ 40%, 40% \< LVEF \< 50%, LVEF ≥50%
  Functional capacity                                 NYHA functional classification                                                      NYHA functional classification I, II, III, IV, or na
  Pharmacological therapy                             Status of ACE/ATII inhibitor treatment at first contact                             Yes or no
  Initiation of ACE/ATII inhibitor treatment          Yes and starting date or no                                                         
  Status of beta-blocker treatment at first contact   Yes or no                                                                           
  Initiation of beta-blocker treatment                Yes and starting date or no                                                         
  Status of MRA at first contact                      Yes or no                                                                           
  Initiation of MRA treatment                         Yes and starting date or no                                                         
  Nonpharmacological therapy                          Physical training                                                                   Yes and starting date of training in hospital or date for referral to training in municipality or no
  Patient education                                   Yes and starting date or no                                                         
  Readmission                                         4-week rate of acute readmission                                                    Yes and date for readmission or no
  Mortality                                           1-year mortality                                                                    Alive or dead according to the Danish Civil Registration System

**Abbreviations:** ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; AF/AFL, atrial fibrillation/atrial flutter; COPD, chronic obstructive pulmonary disease; ICD-10, International Classification of Diseases 10th edition; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; na, not available; NYHA functional classification, New York Heart Association functional classification; SR, sinus rhythm.

###### 

Process and outcome indicators in the Danish Heart Failure Registry

  Indicator area                                                                                 Indicator                                                                                                              Time frame                                                                    Type      Standard (%)
  ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------- --------------
  Echocardiography                                                                               Proportion of patients who undergo echocardiography                                                                    ≤6 months before or ≤7 weekdays after admission or first outpatient contact   Process   ≥90
  NYHA functional classification                                                                 Proportion of patients who undergo NYHA functional classification                                                      ≤12 weeks after admission or first outpatient contact                         Process   ≥90
  Medication                                                                                     Proportion of patients with reduced systolic function (LVEF ≤40%) treated with ACE/ATII inhibitors                     ≤8 weeks after admission or first outpatient contact                          Process   ≥90
  Proportion of patients with reduced systolic function (LVEF ≤40%) treated with beta-blockers   ≤12 after admission or first outpatient contact                                                                        Process                                                                       ≥80       
  Proportion of patients with reduced systolic function (LVEF ≤35%) treated with MRA             ≤12 weeks after admission or first outpatient contact                                                                  Process                                                                       ≥35       
  Physical training                                                                              Proportion of patients with reduced systolic function (LVEF ≤40%) referred to individual physical training             ≤12 weeks after admission or first outpatient contact                         Process   ≥30
  Patient education                                                                              Proportion of patients with reduced systolic function (LVEF ≤40%) who were started on a structured patient education   ≤12 weeks after admission or first outpatient contact                         Process   ≥80
  Readmission                                                                                    Proportion of patients hospitalized acutely within 4 weeks after discharge or first outpatient contact                 ≤4 weeks after discharge from the hospital or first outpatient contact        Outcome   ≤10
  Mortality                                                                                      Proportion of patients who die 1 year after admission to hospital or first outpatient contact                          ≤1 year after admission or first outpatient contact                           Outcome   ≤20

**Abbreviations:** ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA functional classification, New York Heart Association functional classification.

###### 

Coverage and completeness of indicator variables and prognostic factors 2004 to 2015

  Annual report, year                                                                      2004    2005                                            2006                                            2007                                            2008                                              2009    2010    2011    2012    2013    2014    2015
  ---------------------------------------------------------------------------------------- ------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------------------------------------------------- ------- ------- ------- ------- ------- ------- -------
  Number of patients                                                                       2,598   2,452                                           2,429                                           2,731                                           2,996                                             3,229   3,447   3,876   3,909   3,957   3,631   3,735
  Coverage, national level (%)                                                             na      76[\*](#tfn3-clep-8-497){ref-type="table-fn"}   69[\*](#tfn3-clep-8-497){ref-type="table-fn"}   73[\*](#tfn3-clep-8-497){ref-type="table-fn"}   72[\*\*](#tfn4-clep-8-497){ref-type="table-fn"}   79      84      82      83      84      81      82
  Completeness of indicator variables[\*\*\*](#tfn5-clep-8-497){ref-type="table-fn"} (%)                                                                                                                                                                                                                                                             
   Echocardiography                                                                        94      100                                             100                                             100                                             100                                               99      100     99      100     100     100     100
    NYHA functional classification                                                         94      100                                             100                                             100                                             99                                                100     100     100     100     100     100     100
   ACE/ATII inhibitors                                                                     na      67                                              81                                              85                                              85                                                87      86      89      92      93      93      94
   Beta-blockers                                                                           na      36                                              52                                              60                                              87                                                90      87      89      92      93      93      94
   MRA                                                                                     na      6                                               17                                              24                                              85                                                89      86      87      90      90      91      92
   Physical training                                                                       51      68                                              83                                              83                                              86                                                87      84      87      89      89      88      91
   Patient education                                                                       63      78                                              89                                              88                                              87                                                88      85      88      91      91      92      93
   Readmission                                                                             na      100                                             100                                             100                                             99                                                100     100     99      99      100     100     100
   Mortality                                                                               na      100                                             100                                             100                                             100                                               100     100     100     100     100     100     100
  Completeness of prognostic factors (%)                                                                                                                                                                                                                                                                                                             
   Smoking                                                                                 na      na                                              79                                              82                                              85                                                84      86      88      89      92      93      92
   Alcohol                                                                                 na      na                                              71                                              75                                              78                                                80      82      83      85      89      88      89
   LVEF                                                                                    72      73                                              81                                              86                                              90                                                92      93      97      98      99      99      99
   Creatinine                                                                              na      na                                              na                                              na                                              na                                                na      100     100     100     100     100     98
   AMI                                                                                     80      81                                              89                                              92                                              98                                                98      98      99      98      99      99      99
   Stroke                                                                                  72      72                                              85                                              88                                              98                                                98      98      99      98      98      98      98
   Hypertension                                                                            76      77                                              87                                              91                                              99                                                99      99      99      99      99      99      99
   COPD                                                                                    71      72                                              85                                              88                                              98                                                98      98      99      98      99      99      98
   Diabetes                                                                                76      77                                              89                                              93                                              99                                                99      99      99      99      99      99      99

**Notes:**

Self-reported coverage. From 2009, coverage is estimated from the registration of patients in the Danish National Patient Register.

Self-reported coverage. In 2008, coverage was also estimated from the Danish National Patient Register, reaching only 43%.

Data completeness refers to whether or not all the information necessary to estimate the indicator was available in the data resource.

**Abbreviations:** ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; na, not available; NYHA functional classification, New York Heart Association functional classification.
